Magrolimab, a first‐in‐class investigational monoclonal antibody against CD47 and macrophage checkpoint inhibitor is designed to interfere with recognition of CD47 by the SIRPα receptor on macrophages, thus blocking the “don't eat me” signal used by cancer cells. The gene discussed is CD47; the disease is cancer.